<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
21.01.2020 18:20:22

AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate Cancer

AstraZeneca (NYSE: AZN) and Merck (NYSE: MRK) continue their quest to gain additional approvals for their blockbuster cancer drug Lynparza. The duo submitted a new application to the Food and Drug Administration for the drug as a treatment for prostate cancer that's resistant to androgen depletion therapy and has metastasized to other areas of the body.The FDA gave the application a priority review, which cuts four months off the review cycle. The pharmaceutical companies expect to hear back from the agency in the second quarter of this year although a decision could come earlier.Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Merck Co.mehr Analysen

07.01.20 Merck Sector Perform RBC Capital Markets
29.10.19 Merck Neutral Goldman Sachs Group Inc.
30.09.19 Merck Neutral JP Morgan Chase & Co.
25.01.19 Merck Market Perform BMO Capital Markets
25.10.18 Merck Conviction Buy List Goldman Sachs Group Inc.

Eintrag hinzufügen

SMI mit neuem Hoch – UBS mit neuem Chef | BX Swiss TV

Finanzen.net News

pagehit
;